Literature DB >> 22642893

Heparin-induced skin lesions.

Marc Schindewolf1, Edelgard Lindhoff-Last, Ralf J Ludwig, Wolf-Henning Boehncke.   

Abstract

Heparins are widely used for prophylaxis and treatment of thromboembolic diseases. Besides bleeding complications, heparin-induced skin lesions are the most frequent unwanted adverse effects of subcutaneous heparin treatment. Evidence suggests that these lesions are more common than previously thought. Lesions are most frequently due to either allergic reactions or to possibly life-threatening heparin-induced thrombocytopenia. Early recognition and adequate treatment are highly important, because although both complications initially show a similar clinical picture, their treatment should be fundamentally different. Furthermore, risk factors associated with the patient, drug, and treatment regimen have been identified. We review the clinical range of heparin-induced skin lesions, emphasise evidence and controversies in epidemiology, diagnosis, and differential diagnosis, and discuss the management of patients with these skin lesions.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22642893     DOI: 10.1016/S0140-6736(12)60409-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Bilateral adrenal haemorrhage associated with heparin-induced thrombocytopaenia during treatment of Fournier gangrene.

Authors:  Timothy Lee Tattersall; Isaac A Thangasamy; Jamie Reynolds
Journal:  BMJ Case Rep       Date:  2014-10-14

2.  Design of hydrogels to stabilize and enhance bone morphogenetic protein activity by heparin mimetics.

Authors:  Soyon Kim; Zhong-Kai Cui; Paul Jay Kim; Lawrence Young Jung; Min Lee
Journal:  Acta Biomater       Date:  2018-03-26       Impact factor: 8.947

3.  Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient.

Authors:  Ji-Su Shim; Soo Jie Chung; Byung-Keun Kim; Sae-Hoon Kim; Kyu Sang Lee; Yeonyee E Yoon; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2017-04-26

4.  Enoxaparin Induced Skin Lesions in Pregnancy: A Rare But Clinically Recognizable Association.

Authors:  Sumeet Prakash Mirgh; Abhay A Bhave
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-27       Impact factor: 0.900

5.  Sulfonate Hydrogel-siRNA Conjugate Facilitates Osteogenic Differentiation of Mesenchymal Stem Cells by Controlled Gene Silencing and Activation of BMP Signaling.

Authors:  Soyon Kim; Jiabing Fan; Chung-Sung Lee; Chen Chen; Min Lee
Journal:  ACS Appl Bio Mater       Date:  2021-05-27

Review 6.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

7.  Heparinized saline versus normal saline for maintaining peripheral venous catheter patency in China: An open-label, randomized controlled study.

Authors:  Lichun Xu; Yan Hu; Xiaojin Huang; Jianguo Fu; Jinhui Zhang
Journal:  J Int Med Res       Date:  2017-01-30       Impact factor: 1.671

8.  Enoxaparin-Induced DRESS Syndrome.

Authors:  Sophie Ronceray; Monica Dinulescu; François Le Gall; Elisabeth Polard; Alain Dupuy; Henri Adamski
Journal:  Case Rep Dermatol       Date:  2012-10-26

9.  Low Molecular Weight Heparin Induced Skin Necrosis without Platelet Fall Revealing Immunoallergic Heparin Induced Thrombocytopenia.

Authors:  Thomas Godet; Sébastien Perbet; Aurélien Lebreton; Guillaume Gayraud; Sophie Cayot; Aymeric Tremblay; Aurélie Ravinet; Sébastien Christophe; Renaud Guérin; Julien Pascal; Matthieu Jabaudon; Amr Hassan; Anne-Françoise Sapin; Jean-Etienne Bazin; Jean-Michel Constantin
Journal:  Case Rep Hematol       Date:  2013-11-03

10.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.